Search Results - "Quintero Aldana, Guillermo"

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial by Aranda, Enrique, Viéitez, Jose Maria, Gómez-España, Auxiliadora, Gil Calle, Silvia, Salud-Salvia, Antonieta, Graña, Begoña, Garcia-Alfonso, Pilar, Rivera, Fernando, Quintero-Aldana, Guillermo Alfonso, Reina-Zoilo, Juan José, González-Flores, Encarnación, Salgado Fernández, Mercedes, Guillén‑Ponce, Carmen, Garcia-Carbonero, Rocio, Safont, María José, La Casta Munoa, Adelaida, García-Paredes, Beatriz, López López, Rafael, Sastre, Javier, Díaz-Rubio, Eduardo

“…Purpose5-Fluorouracil/leucovorin, oxaliplatin, irinotecan (FOLFOXIRI) plus bevacizumab is more effective than doublets plus bevacizumab as first-line therapy…”
Get full text

Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers by Fernández Montes, Ana, Martínez Lago, Nieves, Covela Rúa, Marta, de la Cámara Gómez, Juan, González Villaroel, Paula, Méndez Méndez, José Carlos, Jorge Fernández, Mónica, Salgado Fernández, Mercedes, Reboredo López, Margarita, Quintero Aldana, Guillermo, Luz Pellón Augusto, María, Graña Suárez, Begoña, García Gómez, Jesús

“…Purpose The phase III VELOUR trial demonstrated efficacy with combined FOLFIRI‐aflibercept in patients with metastatic colorectal cancer previously treated…”
Get full text

Prognostic and predictive markers of response to treatment in patients with locally advanced unresectable and metastatic pancreatic adenocarcinoma treated with gemcitabine/nab-paclitaxel: Results of a retrospective analysis by Montes, Ana Fernández, Villarroel, Paula González, Ayerbes, Manuel Valladares, Gómez, Juan De la Cámara, Aldana, Guillermo Quintero, Tuñas, Lidia Vázquez, Fernández, Mercedes Salgado, Fernández, Mónica Jorge

“…Recent studies support the use of gemcitabine and nab-paclitaxel in adults with locally advanced unresectable or metastatic pancreatic adenocarcinoma although…”
Get full text

Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study) by López, Rafael, Méndez, Carlos Méndez, Fernández, Mónica Jorge, Reinoso, Carlos Romero, Aldana, Guillermo Quintero, Fernández, Mercedes Salgado, DE LA Cámara Gómez, Juan, López, Margarita Reboredo, Vázquez, Manuel Ramos, Folgar, Sonia Candamio

“…To evaluate the efficacy and safety of erlotinib plus capecitabine for metastatic pancreatic cancer. This was a multicenter, uncontrolled, phase II trial…”
Get full text

Neo-adjuvant treatment of infiltrating transitional-cell carcinoma of the bladder with paclitaxel and cisplatin: A phase II trial by SOUSA-ESCANDÓN, ALEJANDRO, VAZQUEZ, SERGIO, QUINTERO-ALDANA, GUILLERMO, PICALLO, JOSE A, NEIRA, JAVIER, GARCIA-NOVIO, FRANCISCO, MATEO, A, RICO, MANUEL, MEL, JOSE R

“…Background : A phase II multicentric trial of paclitaxel and cisplatin was conducted in previously untreated patients, with locally advanced transitional‐cell…”
Get full text

Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study by Feliu, Jaime, Jorge Fernández, Mónica, Macarulla, Teresa, Massuti, Bartomeu, Albero, Ana, González González, José Federico, Quintero-Aldana, Guillermo, Delgado-Mingorance, Juan Ignacio, Fernández Montes, Ana, García Piernavieja, Carmen, Valladares-Ayerbes, Manuel, López Muñoz, Ana María, Mondéjar Solís, Rebeca, Vicente, Pilar, Casado Gonzalez, Esther, González Cebrián, Irene, López-Vivanco, Guillermo

“…Purpose To evaluate the health-related quality of life (HRQoL), global health status (GHS), and deterioration-free survival of an elderly population (>…”
Get full text

Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: BIBABRAX study by Feliu Batlle, Jaime, Jorge Fernandez, Monica, Macarulla, Teresa, Massuti, Bartomeu, Albero, Ana, Gonzalez, Federico, Quintero Aldana, Guillermo Alfonso, Mingorance, J. Ignacio Delgado, Fernandez Montes, Ana, Garcia Piernavieja, Carmen, Valladares-Ayerbes, Manuel, García Girón, Carlos, Mondejar, Rebeca, Vicente, Pilar, Casado, Esther, Gonzalez Cebrian, Irene, Lopez-Vivanco, Guillermo

“…Abstract only 4615 Background: FOLFIRINOX and nab-paclitaxel plus gemcitabine (nab-P+G) are the standard of care in the first-line treatment of mPC patients…”
Get full text

Randomized phase II study on the influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab (Bev) or cetuximab (Cet), as first line therapy of patients (pts) with RAS wild-type metastatic colorectal carcinoma (mCRC) and <3 baseline circulating tumor cells (bCTCs) by Aranda, Enrique, Garcia-Alfonso, Pilar, Vieitez, Jose María, Ortiz, Maria Jose, López-López, Carlos, Reina-Zoilo, Juan José, Salud Salvia, Antonieta, Quintero Aldana, Guillermo Alfonso, Robles, Luis, Safont, Maria Jose, La Casta Munoa, Adelaida, Alés, Inmaculada, Polo Marques, Eduardo, Gallego Plazas, Javier, García de Paredes, Beatriz, Lopez, Rafael, Mónica, Guillot, Valladares-Ayerbes, Manuel, Sastre, Javier, Díaz-Rubio, Eduardo

“…Abstract only 3549 Background: The outcome for mCRC has changed since the introduction of new chemotherapy schedules and targeted therapies, however new…”
Get full text

Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs) by Sastre, Javier, Vieitez, Jose María, Gomez-España, Maria Auxilidora, Gil Calle, Silvia, Salud Salvia, Antonieta, Suárez, Begoña Graña, Garcia-Alfonso, Pilar, Martinez de Castro, Eva, Quintero Aldana, Guillermo Alfonso, Reina-Zoilo, Juan José, González Flores, Encarnación, Fernández, Mercedes Salgado, Guillen, Carmen, Garcia-Carbonero, Rocio, Safont, Maria Jose, La Casta Munoa, Adelaida, García de Paredes, Beatriz, Lopez, Rafael, Aranda, Enrique, Díaz-Rubio, Eduardo

“…Abstract only 3507 Background: FOLFOXIRI+BEV has demonstrated a survival benefit compared with FOLFIRI plus BEV (TRIBE Lancet Oncol 2015) in first-line mCRC…”
Get full text

The prognostic value of systemic inflammatory factors in BRAF (V600E) mutant metastatic colorectal cancer (mCRC) by Martinez Lago, Nieves, Covela Rúa, Marta, Brozos Vazquez, Elena, Fernandez Montes, Ana Fernandez, de la Cámara Gómez, Juan Cruz, Méndez Méndez, Carlos, Jorge Fernández, Mónica, Cousillas Castiñeira, Antia, Suárez, Begoña Graña, Quintero Aldana, Guillermo Alfonso, Candamio Folgar, Sonia, Salgado Fernandez, Mercedes, Pellon Augusto, Maria Luz, Gonzalez Villarroel, Paula, Gallardo Martin, Elena, Carmona Campos, Marta, Vazquez Rivera, Francisca, Grande Ventura, Carlos, Carral Maseda, Alberto, Reboredo Lopez, Margarita

“…Abstract only 622 Background: Multiple studies have reported prognostic association of neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLT)…”
Get full text

What is the role of the anti-angiogenic therapy in BRAF (V600E) mutant metastatic colorectal cancer patients in a real-world setting? by Martinez Lago, Nieves, Covela Rúa, Marta, Brozos Vazquez, Elena, Fernandez Montes, Ana Fernandez, De La Camara Gomez, Juan Cruz, Méndez Méndez, Carlos, Jorge Fernández, Mónica, Cousillas Castiñeira, Antia, Suárez, Begoña Graña, Quintero Aldana, Guillermo Alfonso, Candamio Folgar, Sonia, Salgado Fernandez, Mercedes, Pellon Augusto, Maria Luz, Gonzalez Villarroel, Paula, Gallardo Martin, Elena, Carmona Campos, Marta, Vazquez Rivera, Francisca, Grande Ventura, Carlos, Carral Maseda, Alberto, Reboredo Lopez, Margarita

“…Abstract only 620 Background: Activating B-type Raf kinase (BRAF) mutations, mostly missense V600E, occur in approximately 8% to 12% of patients with…”
Get full text

First-line panitumumab plus docetaxel and cisplatin in advanced gastric or gastroesophageal junction adenocarcinoma: Results of a phase II trial (SPIGA) by Quintero Aldana, Guillermo Alfonso, Candamio Folgar, Sonia, Méndez, Jose Carlos Méndez, Reboredo, Margarita, Jorge Fernández, Mónica, Constenla, Manuel, Romero Reinoso, Carlos, Fernández, Mercedes Salgado

“…Abstract only…”
Get full text

BRAF (V600E) mutant metastatic colorectal cancer: What is the role of the antiangiogenic therapy in a real-world setting? by Martinez Lago, Nieves, Fernandez Montes, Ana Fernandez, Covela Rúa, Marta, Brozos Vazquez, Elena, De La Camara, Juan Cruz, Jorge Fernández, Mónica, Cousillas, Antia, Méndez, Jose Carlos Méndez, Carmona Campos, Marta, Romero Reinoso, Carlos, Gonzalez Villarroel, Paula, Vidal Insua, Yolanda, Gallardo Martin, Elena, Graña, Begoña, Vazquez Rivera, Francisca, Pellon Augusto, Maria Luz, Quintero Aldana, Guillermo Alfonso, Reboredo Lopez, Margarita, Candamio Folgar, Sonia, Salgado Fernandez, Mercedes

“…Abstract only…”
Get full text

Safety analysis of a phase III randomized trial comparing FOLFOX + Bevacizumab vs FOLFOXIRI + Bevacizumab as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 circulating tumor cells (CTCs) (VISNÚ-1 TTD TRIAL) by Gomez, A., Vieitez, Jose María, Gil, Silvia, Salud Salvia, Antonieta, Suárez, Begoña Graña, Garcia Alfonso, Pilar, Martínez de Castro, Eva, Quintero Aldana, Guillermo Alfonso, Reina, Juan J, González Flores, Encarnación, Fernández, Mercedes Salgado, Rodríguez Garrote, Mercedes, Flor Oncala, Ma. José, Safont, Maria Jose, La Casta Munoa, Adelaida, Lopez, Rafael, Monica, Guillot, García-Paredes, Beatriz, Diaz-Rubio, Eduardo, Aranda, Enrique

“…Abstract only…”
Get full text

First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study by Méndez Méndez, José Carlos, Salgado Fernández, Mercedes, de la Cámara Gómez, Juan, Pellón Augusto, Mari Luz, Covela Rua, Marta, Quintero Aldana, Guillermo, Fernández Montes, Ana, Reboredo López, Margarida, Valladares Ayerbes, Manuel, Jorge Fernández, Mónica, González Villarroel, Paula, Romero Reinoso, Carlos, Ramos Vázquez, Manuel

“…Despite the high morbidity and mortality of metastatic colorectal cancer (mCRC) in older patients, they have been underrepresented in clinical trials and their…”
Get full text

Activity of aflibercept (Afli) in combination with FOLFIRI (F) for patients with metastatic colorectal cancer (mCRC) in a real-life setting in Spain: Final results of the retrospective study Named Patient Program by Sastre, Javier, Feliu, Jaime, Martinez, Purificación, Buges, Cristina, Mendez, Jose Carlos, Alcaide, Julia, Garcia, Teresa, Valladares, Manuel, Marrupe, David, Delgado, Ignacio, Salgado Fernandez, Mercedes, Martin Valades, Jose Ignacio, Juarez, Asuncion, Martin Martinez, Jose Miguel, Lopez, Ana, Quintero Aldana, Guillermo Alfonso, Donnay, Olga, Vera, Ruth, del Pozo, Nieves, Diaz De Corcuera Frutos, Isabela

“…Abstract only 689 Background: InVELOUR trial the addition of aflibercept to FOLFIRI regimen, demonstrated a statistically significant overall survival…”
Get full text

Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer by Roca, José-María, Alonso, Vicente, Pericay, Carles, Escudero, Pilar, Salud, Antonieta, Losa, Ferrán, López, Luis-Jesús, Guasch, Imma, Méndez, Miguel, Quintero-Aldana, Guillermo, Grande, Carlos, Vicente, Pilar, Arrivi, Antonio, Martin, Cristina, Moreno, Isabel, García, Pilar, Antón, Isabel, Constenla, Manuel, Yubero, Alfonso, Cirera, Luis

“…We gathered data from multiple institutions on the cetuximab regimen of patients with metastatic colorectal cancer. 126 patients from 19 centers were included…”
Get more information